Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CASI Pharma Acquires 29 Generic Drug Candidates from Sandoz

publication date: Jan 29, 2018

CASI Pharma, a US-China company, acquired a portfolio of 29 generic drugs from Sandoz, the generic drug division of Novartis. Each of the products has submitted Abbreviated New Drug Applications (ANDAs) for US approval. CASI, which will focus on bringing the generic drugs to China, will select members of the portfolio for development, emphasizing entecavir, an antiviral for hepatitis B. It may also manufacture the drugs in China for US use. The financial terms of the agreement were not disclosed. More details....

Stock Symbol: (NSDQ: CASI) (NYSE: NVS)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital